-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Angelini pharmaceutical company, announced the European Commission (EC) has approved the use of anti- medsci.
medsci.
The approval is based on three key trials involving more than 1,900 patients.
In addition, the 100% response rate for patients receiving Ontozry 100mg/day, 200mg/day, and 400mg/day were 4%, 11%, and 21%, respectively.
Angelini Chief Medical Officer Agnese Cattaneo added: “It is very important for patients to choose new treatments because seizures can have a devastating impact on their lives.
Original source:
Original source:href="" target="_blank" rel="noopener">